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It has been estimated that the number of cancer survivors will double from 12 million in 2012 to 24 million by the 
end of the next decade in the United States alone, raising 
awareness and concern for health problems during follow 
up of these patients. Among cancer survivors, half will die 
of cancer recurrence, but a third will die of cardiovascular 
disease (1). The recognition of the challenges and oppor-
tunities related to heart disease in cancer survivors has led 
to the inception of onco-cardiology as a new discipline. 
Onco-cardiology is a medical discipline that focuses on the 
identification, prevention, and treatment of cardiovascular 
complications related to cancer therapy.
A combination of surgical procedures, radiation ther-
apy, and chemotherapy is the main therapeutic option 
for many malignancies including intrathoracic cancers. 
It is increasingly recognized that chemotherapy–radiation 
therapy may have adverse cardiac effects, although radia-
tion therapy technology for treating chest malignancies 
has markedly improved by delivering therapeutic doses 
to well-defined targets while minimizing radiation injury 
to surrounding normal organs (2). However, despite ad-
vances in radiation therapy planning, there are still con-
cerns about the acute and long-term effects of radiation 
therapy to surrounding thoracic organs, particularly the 
heart. Radiation-induced heart disease may occur at even 
relatively low radiation doses, in contrast to the outdated 
notion that the heart is a radio-resistant organ. The latency 
period for radiation-induced heart disease may range from 
months to many years and is dependent on radiation dose, 
age, preexisting cardiovascular disease, traditional risk fac-
tors, and concurrent chemotherapy (2).
Cardiac disease after radiation therapy may manifest in 
various ways, including as coronary artery disease, valve 
disease, pericardial disease, or as direct injury to the myo-
cardium. The hallmark of radiation-induced myocardial 
damage is fibrosis, which is initiated through various 
cellular mechanisms that result in endothelial damage of 
the myocardial microvasculature and the large epicardial 
coronary vessels (3). Structures that may be affected are the 
myocardium, main coronary arteries, microvasculature, 
conduction system, pericardium, cardiac valves, and proxi-
mal aorta. Coronary artery disease after radiation therapy 
may manifest with more fibrous plaques because of intimal 
hyperplasia and ostial stenoses, in addition to stenoses that 
are smoother, longer, and more concentric than are those 
in conventional coronary artery disease. Radiation-induced 
heart disease conforms to radiation portals. For example, 
women with left-sided chest radiation have a higher risk 
of cardiovascular complications compared with women 
who undergo right-sided radiation. Myocardial intersti-
tial fibrosis after radiation involves a number of cellular 
processes that result in cardiomyopathy because of direct 
myocardial injury (3). Various cytokines and inflamma-
tory pathways have been implicated in myocardial fibrosis 
after irradiation, resulting in a proliferation of fibroblast 
activity and an expansion of the myocardial interstitium 
and extracellular matrix. Myocardial fibrosis consists of a 
proliferation of collagen bands, separating and replacing 
myocytes (4).
Noninvasive cardiac imaging plays an important role in 
the diagnosis of symptomatic and asymptomatic cardiovas-
cular disease during cancer therapy. The echocardiogram 
is the most widely used tool for serial evaluation of the 
heart during cancer therapy (5). According to the Ameri-
can Society of Echocardiography guidelines, ejection frac-
tion should be determined by using the biplane method of 
discs. However, the temporal variability of estimating ejec-
tion fraction with echocardiography may be up to 10%, 
which can be higher than the thresholds used to define 
cardiotoxicity (5). Another major limitation of the use of 
ejection fraction as a biomarker is the late occurrence of re-
duction in ejection fraction (5). Hence, there is a growing 
interest in identifying markers of early myocardial injury to 
predict heart failure. Myocardial strain analysis with tissue 
Doppler imaging and speckle tracking strain imaging have 
been advocated for the detection of global and regional 
mechanical dysfunction as an early, more sensitive marker 
of heart disease. This echocardiographic technique has a 
number of technical limitations, but may detect early sys-
tolic left ventricular dysfunction before a decrease in ejec-
tion fraction is observed in patients with cardiotoxicity.
Coronary CT angiography, MRI, and radionuclide per-
fusion imaging may provide alternative noninvasive imag-
ing approaches that can depict the major manifestations 
of radiation-induced heart disease more comprehensively 
and directly compared with echocardiography. CT angiog-
raphy is well suited to assess coronary artery disease, evaluate 
the extent, characterize plaque features, and assess coronary 
calcifications; it may also help to assess the functional 
status of a coronary artery stenosis. Screening for radiation- 
induced heart disease with coronary CT angiography yields 
high prevalence of coronary artery disease, but the benefit of 
screening on survival is unknown. For example, the preva-
lence of significant coronary artery disease is high after me-
diastinal irradiation in survivors of Hodgkin lymphoma, 
while asymptomatic even in the presence of life-threatening 
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coronary artery disease (6). A recent health-related quality of 
life analysis of survivors of Hodgkin lymphoma was performed 
to assess the emotional and practical burden as well as perceived 
benefits of screening and counseling on patient satisfaction. 
Screening by means of CT angiography and subsequent cardiac 
intervention was highly valued and the benefits were felt to 
outweigh the emotional and practical burden (7).
Cardiac MRI may be useful to identify perfusion defects 
similar to CT perfusion and radionuclide perfusion techniques. 
However, the main advantage of cardiac MRI is myocardial tissue 
characterization by using multiparametric imaging, including 
late gadolinium enhancement to detect gross scar, T1 mapping 
to define interstitial fibrosis, and extracellular matrix expansion 
and T2 mapping to assess myocardial edema.
In the current issue of Radiology, Takagi et al report the use 
of serial T1 mapping of the left ventricle to assess the potential 
detrimental effects of chemotherapy–radiation therapy to the 
heart in patients who underwent treatment for esophageal can-
cer (8). Radiation therapy–induced complications are increas-
ingly reported in survivors of esophageal cancer as the survival 
rate of this malignancy is growing (2). Takagi et al performed 
serial T1 mapping of the heart in a prospectively defined study 
before and at two time points (0.5 year and 1.5 years) after che-
motherapy–radiation therapy, thereby providing insight into 
the evolution over time of myocardial injury after radiation 
therapy (8). In addition, the authors evaluated a differential 
effect on the basal left ventricular septum, which is included 
in the radiation field versus the nonirradiated lateral wall of 
the left ventricle. The imaging protocol included cine MRI 
to assess function, precontrast and postcontrast T1 mapping 
to assess myocardial injury and expansion of the extracellular 
matrix, and late gadolinium enhancement to assess myocardial 
scar tissue. The main observation was that myocardial native 
T1 values and extracellular volume reveal myocardial changes 
earlier (already at 6-month follow-up) than changes in global 
left ventricular function or gross scar seen at late gadolinium 
imaging. Furthermore, the myocardial tissue alterations were 
confined to the basal septum, which received the higher radia-
tion dose. The strengths of the study by Takagi et al were the 
prospective design, the serial assessment starting before radia-
tion therapy, and the use of multiparametric cardiac MRI to 
depict early myocardial changes in an important and growing 
patient population. A number of limitations may be noted 
related to relatively small sample size, lack of cardiac events 
during follow-up period, the uncertainty about the prognos-
tic implications of the findings, and the confounding effect of 
concurrent chemotherapy. However, this study provides an im-
petus to explore the utility of cardiac MRI in diagnosing early 
myocardial injury in patients who underwent chemotherapy–
radiation therapy. In addition, the study illustrates how cardiac 
MRI may be of potential value for early diagnosis of radiation-
induced myocardial injury. Hopefully, future studies will de-
fine how early diagnosis by using cardiac MRI may translate to 
therapy and prevention of radiation-induced heart disease in 
the growing population of cancer survivors in general.
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